Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - F-star Therapeutics, Inc. | sbph-ex321_11.htm |
| EX-31.2 - EX-31.2 - F-star Therapeutics, Inc. | sbph-ex312_6.htm |
| EX-31.1 - EX-31.1 - F-star Therapeutics, Inc. | sbph-ex311_7.htm |
| EX-21.1 - EX-21.1 - F-star Therapeutics, Inc. | sbph-ex211_242.htm |
| EX-4.5 - EX-4.5 - F-star Therapeutics, Inc. | sbph-ex45_479.htm |
| 10-K - 10-K - F-star Therapeutics, Inc. | sbph-10k_20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Nos. 333-215122, 333-218399 and 333-234436) on Form S-3 and Registration Statement (Nos. 333-212047, 333-226508) on Form S-8 of Spring Bank Pharmaceuticals, Inc. of our report dated February 14, 2020, relating to the consolidated financial statements of Spring Bank Pharmaceuticals, Inc. and its subsidiaries, appearing in this Annual Report on Form 10-K of Spring Bank Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ RSM US LLP
Boston, Massachusetts
February 14, 2020